This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Lilly's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?
by Zacks Equity Research
Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.
Bristol-Myers' Opdivo Gets Priority Review for Lung Cancer
by Zacks Equity Research
The FDA accepts Bristol-Myers Squibb's (BMY) supplemental Biologics License Application and grants priority review for the label expansion of Opdivo to treat patients with small cell lung cancer.
Merck's Keytruda Betters Survival in Lung Cancer Combo Study
by Zacks Equity Research
Merck (MRK) releases complete data from a phase III study showing Keytruda in combination with Lilly's Alimta and platinum chemotherapy reducing death risk by half compared with only chemotherapy.
J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2018. It maintains the previously issued earnings guidance for 2018 while increasing the sales range.
Company News For Apr 17, 2018
by Zacks Equity Research
Companies In The News are: JBHT,ERI,MRK,ALKS
Bristol-Myers Reports Positive Data in NSCLC Trial on Opdivo
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced positive results from the phase III trial, CheckMate -078 trial on immuno-oncology drug Opdivo among a predominantly Chinese population.
Dow 30 Stock Roundup: P&G Hikes Dividend; Boeing, American Airlines Ink $12B Deal
by Zacks Equity Research
The Dow enjoyed a week of strong gains as trade war and Syria related fears receded.
Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.
Nektar Starts Phase I/II Combo for Advanced Solid Tumors
by Zacks Equity Research
Nektar (NKTR) initiates dosing in a phase I/II study, evaluating the combination of its two novel immuno-oncology agents, NKTR-262 and NKTR-214, on patients with advanced solid tumors.
Pfizer's Kidney Cancer Drug Misses Endpoint in Phase III
by Zacks Equity Research
Pfizer's (PFE) kidney cancer drug Inlyta (axitinib) fails to demonstrate a clear improvement in the primary endpoint of extending disease-free survival (DFS) in a late-stage study.
vTv Therapeutics Crashes on Alzheimer's Drug Study Failure
by Zacks Equity Research
vTv Therapeutics (VTVT) shares suffered a major blow when the company's late stage study on lead candidate, azeliragon, for the treatment of Alzheimer's failed.
Merck's Keytruda Offers Survival Benefit in Lung Cancer Study
by Zacks Equity Research
Merck's (MRK) phase III study showed that Keytruda monotherapy led to significantly improved overall survival (OS) as a first-line therapy in certain lung cancer patients.
NewLink Shares Plunge After Incyte & Merck's Study Fails
by Zacks Equity Research
Shares of NewLink Genetics Corp. (NLNT) plunged about 42.6% following the news of the failure of Incyte and Merck's phase III combination study for metastatic melanoma.
Incyte's Epacadostat Fails in Melanoma Study, Shares Plunge
by Zacks Equity Research
Incyte's (INCY) epacadostat in combination with Merck's Keytruda fails to meet primary endpoint of PFS in a phase III melanoma study.
Biogen Cracks the Case With AbbVie for Humira Biosimilar
by Zacks Equity Research
Biogen (BIIB) and partner Samsung Bioepis resolve an ongoing patent row with AbbVie regarding Biogen's biosimilar version of AbbVie's arthritis drug, Humira, in the EU.
AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use
by Zacks Equity Research
AstraZeneca's (AZN) Bydureon gets FDA approval for expanded use in type II diabetes patients. Meanwhile, regulatory submissions for its leukemia candidate and Lynparza get acceptance in the United States and EU, respectively.
Aeglea Initiates Lung Cancer Combination Study With Keytruda
by Zacks Equity Research
Aeglea BioTherapeutics (AGLE) doses first patients in two early stage lung cancer studies evaluating pegzilarginase as single agent and in combination with Merck's Keytruda.
Fast Pipeline Progress Pushes ImmunoGen Above 150% in a Year
by Zacks Equity Research
ImmunoGen's (IMGN) shares shoot up more than 150% in a year's time on rapid pipeline progress, positive study data and strategic collaborations.
Merck KGaA's Tepotinib Gets Fast Track Designation in Japan
by Zacks Equity Research
Merck KGaA's (MKGAF) lung cancer candidate, tepotinib gets fast track designation in Japan.
Merck, Eisai Get Japanese Nod for Lenvima Label Expansion
by Zacks Equity Research
Merck (MRK) and partner Eisai receive approval in Japan for Lenvima for the first line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Roche's Tecentriq Combo Study Meets Co-Primary Endpoint
by Zacks Equity Research
Roche's (RHHBY) phase III study, evaluating a combination of Tecentriq and Avastin plus carboplatin and paclitaxel for first line treatment of advanced lung cancer met its co-primary endpoint of overall survival.
Merck Gets European Committee Vote for Veterinary Product
by Zacks Equity Research
Merck (MRK) is seeking approval of Bravecto Plus, a spot-on solution for cats. The drug is part of the company's Animal Health unit.
Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion
by Zacks Equity Research
Seattle Genetics' (SGEN) cancer drug, Adcetris, gets FDA approval to include fifth indication, frontline treatment of advanced classical Hodgkin lymphoma, in its label.
Roche Tecentriq Phase III Combo Study Meets Primary Endpoint
by Zacks Equity Research
Roche (RHHBY) announces that the combination study of Tecentriq plus chemotherapy meets its co-primary endpoint of progression-free survival.